AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02561156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653 Placebo
Description: TAK-653 placebo-matching tablets.
Study NCT02561156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.
Study NCT03939208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRISC
Study NCT03939208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAU
Study NCT02515240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: 23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Study NCT02582684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Participants were prescribed 50 mg of DTG orally daily
Study NCT02582684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Participants were prescribed 300 mg of 3TC orally daily.
Study NCT01334827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high volume gel
Description: 4 mL HEC
Study NCT01334827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low volume gel
Description: 2 mL HEC
Study NCT01334827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vaginal film
Description: 1 x 2 intravaginal quick-dissolving film
Study NCT03180684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
Study NCT03180684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Cream
Description: Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
Study NCT01987674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water drink
Study NCT01857154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Calcium Carbonate
Description: Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.
Study NCT01857154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Micronized Calcium Carbonate
Description: Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate.
Study NCT01857154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: All subjects in the study cohort will be administered 800 IU Vitamin D3.
Study NCT01839279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Study NCT01839279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01839279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01839279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT01839279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Study NCT04138186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.0g G-PUR®, oral administration
Description: tid for 12 weeks
Study NCT04138186 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, oral administration
Description: tid for 12 weeks
Study NCT03180684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
Study NCT00957593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Continuation of oxytocin once in active labor
Study NCT00957593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin discontinuation
Description: Oxytocin will be stopped once in active labor
Study NCT02548728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin Spray
Description: 10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
Study NCT02548728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
Study NCT02751931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight >=35 kg received mirabegron tablets or body weight \<35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became >=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became \<35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.
Study NCT01986933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab (CIM331)
Study NCT01986933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01876810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: 600 mg of gemfibrozil (one capsule) twice daily for two weeks.
Study NCT01876810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One lactose pill twice a day for two weeks.
Study NCT02531971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl citrate
Description: 100 micrograms (2 millilitres) via intravenous injection
Study NCT02531971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragesic®
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Study NCT02531971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mylan generic fentanyl
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Study NCT01430754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, daily
Study NCT01430754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, daily
Study NCT01069185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Necessity endotracheal suctioning
Description: Endotracheal suctioning depends on clinical manifestations
Study NCT01069185 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine endotracheal suctioning
Description: Endotracheal suctioning every two hours
Study NCT01298544 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
Study NCT00356122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70 mg/m\^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
Study NCT00356122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m\^2 administered IV on Day 1 for Cycles 1-6
Study NCT00356122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
Study NCT00491556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Initiation of Highly Active Anti-Retroviral Therapy
Description: Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
Study NCT00491556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
Study NCT01030783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib (AV-951)
Description: Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Study NCT01030783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Study NCT01495871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acids
Description: 15 grams amino acids two times per day for 6 weeks
Study NCT01495871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of inert compounds
Description: Placebo two times per day for 6 weeks
Study NCT01495871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Valine
Description: 2.5 grams valine supplementation two times a day for 6 weeks
Study NCT03620591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intraoperative administration of lidocaine
Study NCT04017403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium triple live capsule
Description: Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
Study NCT03388944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCT group
Description: In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
Study NCT01808742 — intervention group
Intervention type: DEVICE
Intervention: Treatment with CryoTouch III Device
Description: Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
Study NCT03620591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraoperative administration of normal saline
Study NCT04017403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos were administrated as same as the bifidobacterium live capsule
Study NCT04297007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block
Description: A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT04297007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid intercostal block
Description: A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT01961531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuboost APBI
Description: 28Gy delivered in 5 daily fractions
Study NCT04097483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Intervention Group
Description: Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
Study NCT01633450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc biofortified rice
Description: 1.12 mg zinc per meal
Study NCT01633450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice extrinsically fortified with zinc
Description: 1.12 mg zinc per meal
Study NCT05198947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Lotion 5%
Description: Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
Study NCT05198947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg
Description: Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
Study NCT02288221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's answer with non pharmacological therapeutic
Description: Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games
Study NCT02288221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient's answer without non pharmacological therapeutic
Description: No installation at patient's home
Study NCT02023229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched-chain aminoacids
Study NCT02023229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fiber high protein diet
Study NCT02023229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fiber high protein diet
Study NCT04712045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New PPE
Description: The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
Study NCT04712045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Old PPE
Description: The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
Study NCT01162525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (pTNS)
Description: A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
Study NCT01241539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg capsule
Study NCT00271752 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Earlier therapeutic changes regarding infection
Description: For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
Study NCT01241539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 75 mg capsule
Study NCT00271752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Earlier therapeutic changes regarding infection
Description: For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
Study NCT01587404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)
Description: Variable contact force as measured at the catheter tip within the left atrium
Study NCT02296008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D high resolution anorectal manometry
Description: Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded.
Study NCT01241539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 110 mg capsule
Study NCT01606462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
Study NCT01606462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
Study NCT03185130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 5mL
Description: Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
Study NCT03185130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline 20mL/kg
Description: Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
Study NCT03185130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine 0.15 mg/kg up to 10 mg IV
Description: Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
Study NCT03185130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.15 mg/kg up to 10 mg IV
Description: Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
Study NCT03185130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 1 mg/kg up to 50 mg IV
Description: Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
Study NCT03948386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric bupivacaine
Description: The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study NCT03948386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine
Description: TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study NCT03948386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric mepivacaine
Description: The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
Study NCT03185130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1 mg/kg up to 50 mg IV
Description: Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
Study NCT02361346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 1
Description: Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
Study NCT03979729 — intervention group
Intervention type: OTHER
Intervention: Routine Screening Mammogram (3D + 2D)
Description: Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
Study NCT03979729 — intervention group
Intervention type: OTHER
Intervention: Routine Screening Mammogram (2D)
Description: Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
Study NCT03979729 — intervention group
Intervention type: OTHER
Intervention: No Screening Mammogram
Description: Subjects will participate in a one-time facilitated focus group.
Study NCT01071070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
Study NCT03752905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: Recombinant human collagen 7 (rC7)
Study NCT02361346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724 Phase 2
Description: Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
Study NCT02013141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Study NCT00782795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
Study NCT00782795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo